Low-Dose Colchicine Post-MI: Reducing Inflammation?
February 3rd 2020Canakinumab, a fully human monoclonal antibody, targets interleukin-1β, has anti-inflammatory effects, and is FDA-approved for rheumatologic disorders. Interleukein-1β is a cytokine that drives the interleukin(IL)-6 signaling pathway in inflammatory response.
Read More